Hinge Bio key facts
as of Oct 2026- Operator of a biotech company intended to work for the development of a new class of flexible, extendible, and cooperatively binding therapeutics and diagnostics.
- Hinge Bio is valued at approximately $46.0M as of Oct 2026, set at its later-stage round, Jan 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $66.8M across 4 recorded rounds; the latest was Early Stage VC ($30.6M) in Dec 2024.
- Notable investors include US National Science Foundation, Springboard Enterprises, United States Department of War, Evolution VC Partners, Baruch Future Ventures — 13 tracked in total.
- Hinge Bio has filed 6 Form Ds with the SEC since 2020, most recently Jan 2025 ($30.6M sold to 82 investors).
- Status: Privately Held (backing).
Valued at $46.0M at its later-stage round, Jan 2025. Nothing has traded since.
- ·The complete investor list: 13 names
- ·Watch Hinge Bio: the Monday email on marks, rounds and moves
Hinge Bio funding rounds
4 roundsWho backs Hinge Bio
13+Hinge Bio valuation
Hinge Bio was valued at $46 million at its later-stage round in Jan 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Hinge Bio raised?
Hinge Bio has raised $66.8 million across 4 recorded rounds since 2017. The largest was a $30.6 million early-stage round in Dec 2024.
Hinge Bio has filed 6 Form Ds with the SEC since 2020, most recently in Jan 2025 ($30.6 million sold to 82 investors).
Hinge Bio investors
13 investors are on record for Hinge Bio, including US National Science Foundation, Springboard Enterprises, United States Department of War and Evolution VC Partners. The early-stage round in Dec 2024 drew 82 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: ParcelBio ($41.2 million), Persephone Biosciences ($37.3 million) and Solarea Bio ($37 million).
About Hinge Bio
Operator of a biotech company intended to work for the development of a new class of flexible, extendible, and cooperatively binding therapeutics and diagnostics. The company focuses on facilitating therapeutics capable of simultaneously binding either one disease target with multiple hands and targeting different oncology, metabolic disease, and neurodegenerative disorders, enabling medical providers to diagnose diseases at an early stage and provide proper treatment.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Burlingame, CA, United States
- Founded
- 2015
- Employees
- 18
- Website
- hingebio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.